BrainStorm claims PhIIa ALS success; Amunix inks development deal with Naia;

@FierceBiotech: Aduro bags $51M for its 'breakthrough' cancer combo. Story | Follow @FierceBiotech

@JohnCFierce: Big round of deals today augurs well for new partnerships/ M&A in 2015. #JPM15 will be abuzz with deal talk (not unusual). #biotech | Follow @JohnCFierce

@DamianFierce: $AMGN buys into CAR-T with $KITE partnership. Release | Follow @DamianFierce

> Shares of BrainStorm Cell Therapeutics ($BCLI) shot up on Friday in anticipation of positive data from a small Phase IIa study of NurOwn in amyotrophic lateral sclerosis (ALS). A total of 14 patients were involved and investigators said that they tracked a slower progression of the disease following treatment. Shares dropped 20% on Monday morning after the biotech released the data and investors got a chance to cash in on some fast money. Release

> Amunix and Naia signed two licenses to further develop two Amunix receptor agonist product candidates: GLP-1-XTEN, a glucagon-like peptide-1 receptor agonist for the treatment of Type 2 diabetes and GLP-2-XTEN, a glucagon-like peptide-2 receptor agonist for the treatment of short bowel syndrome. Amunix has the chance to earn up to $70 million in milestones for each project. Release

Medical Device News

@FierceMedDev: HTG Molecular Diagnostics mulls $60M IPO for next-gen profiling technology. FierceDiagnostics story | Follow @FierceMedDev

@EmilyWFierce: Aethlon Medical snagged FDA approval for clinical trial of bio-filtration device to treat Ebola. Release | Follow @EmilyWFierce

> FDA deems Halyard's recalled KimVent endotracheal tubes potentially deadly. News

> Survey: Most U.S. consumers eager to use wearable devices to monitor their health. Report

Pharma News

@FiercePharma: Pfizer's growth spurt continues with pickup of Switzerland's Redvax. FierceVaccines Story | Follow @FiercePharma

@CarlyHFierce: Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff. Story | Follow @CarlyHFierce

> Move over, Big Pharma: Smaller biopharma's execs are bringing home more bacon. Article

> Pfizer pads growing vaccines unit with CMV pickup. Item

> Merck poised for early Keytruda launch in lung cancer, analyst says. Article

Biotech IT News

> Scripps director: Validation needed to unlock the potential of wearables. Item

> NHS England picks 100,000 Genomes Project sites ahead of February start date. Article

> Analytics and Big Data investments spur bumper year for digital health funding. Story

> FDA outlines industry-focused ambitions as Mini-Sentinel graduates. More

> Roche buys Bina to add informatics piece to its genomics resurgence. News

CRO News

> Evotec teams up with Ohio State on a new cancer drug. Story

> WuXi goes mobile with a chemistry app. News

> GVK feels the sting after data scandal. More

> Covance could face fines over animal deaths. Story

> PPD bets on Japan with new joint venture. Article

Animal Health News

> Lilly closes Novartis deal, creating second-largest animal health giant. News

> FDA trusts vets to curb antibiotic use, but are ties to drug companies too tight? More

> High debt, low starting salaries plague new veterinarians. Item

> Colorado State nabs record $42.5M gift for translational research institute. Story

> Putney CEO Hoffman sets sights high for 'largest pipeline' in animal health. Article

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.